Since previous studies reported that activated mTOR signaling is a possible factor for drug resistance in several cancer cells and that regulating mTORC1/S6K signaling could be a potential strategy for cancer therapy [43,44], we hypothesized that S6K activity is related to paclitaxel resistance in SKOV3-TR cells. This evidence concerns the gene MTOR and cancer.